16th October 2017
The news of the completion of Nuformix’s acquisition by Levrett plc was covered in Cambridge News by Matt Gooding.
The article summarises how Nuformix is pioneering the use of drug cocrystals in pharmaceutical development, underpinned by its IP portfolio containing 14 granted patents, and has identified two drug cocrystals, NXP001 and NXP002, which are being progressed to clinical trials. Dan Gooding, chief executive of Nuformix, said: “The team is proud of our intellectual property portfolio and believe that our two lead cocrystal programmes offer great commercial and therapeutic promise.”
Link to the article here